ROCKVILLE, Md. and HONG KONG, Feb. 21, 2018 /PRNewswire-USNewswire/ -- Ascentage Pharma,a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the presentation of preliminary data from its ongoing Phase 1 trials of its lead product candidate
About APG-1252APG-1252 is a highly potent investigational small molecule that selectively binds to and inhibits Bcl-2 and Bcl-xL proteins, both of which play pivotal roles in regulating programmed cell death, or apoptosis. APG-1252 is designed to overcome on-target toxicity of platelets that may occur during Bcl-xL inhibition, while maintaining strong anti-tumor potency. In preclinical studies, APG-1252 achieved complete and persistent tumor regression in multiple tumor xenograft models with a twice weekly or weekly dose schedule, including small cell lung cancer (SCLC), colon cancer, breast cancer and acute lymphoblastic leukemia. APG-1252 also demonstrated strong synergy with chemotherapeutic agents, indicating that it may have broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-1252 is being investigated in Phase 1 clinical studies in patients with SCLC or other solid tumors.
About Ascentage PharmaAscentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.
Media ContactAmy Bonanno E-mail: firstname.lastname@example.orgPhone: +1 914 450 0349
Investor ContactChad RubinE-mail: email@example.comPhone: +1 646 378 2947
View original content:http://www.prnewswire.com/news-releases/ascentage-pharma-to-present-at-the-iaslc-18th-lung-cancer-targeted-therapies-meeting-300601762.html
SOURCE Ascentage Pharma
Subscribe to our Free Newsletters!
Black food is the new green owing to its health benefits from cardiovascular health to weight loss. ...
Scurvy is a condition that occurs due to the deficiency of vitamin C. It occurs only rarely, since ...
Pets can give you diseases. Surprised? You may love your pet but beware! Your pets might be ...View All